Grip force abnormalities in de novo Parkinson's disease
Grip force abnormalities in de novo Parkinson's disease
复制标题
DOI：
10.1002/mds.10710
复制
发表时间：
2004-05-01
影响因子：
8.6
通讯作者：
Noth, J
中科院分区：
文献类型：
--
作者：
Fellows, SJ;Noth, J
近年来，已经表明，各种运动障碍与手部精细运动控制的异常有关。在帕金森氏病（PD），这些变化包括一个缓慢的速度的握力发展和使用异常大的握力都在提升和静态持有的对象。然而，已经表明这些变化是患者左旋多巴药物的直接影响或与左旋多巴诱导的运动障碍相关。因此，我们研究了帕金森病患者在精确提升任务中的表现。所有患者（n = 6）均为新诊断，表现为强直、运动迟缓或两者兼有，但未受震颤或运动障碍影响。没有一个病人接受过抗帕金森药物治疗。在提升和保持阶段，夹持力都异常高。这种夸大程度与先前在接受药物治疗的患者中观察到的程度相同。因此，我们得出结论，在这里观察到的握力异常是PD的内在特征，而不是多巴胺药物或其副作用的结果。(C)2003年，为社会运动员。
In recent years it has been shown that a variety of movement disorders are associated with abnormalities of the fine motor control of the hand. In Parkinson's disease (PD), these changes consist of a slowing of the rate of grip force development and the use of abnormally large grip forces both during lifting and static holding of an object. It has been suggested, however, that these changes are a direct effect of the patient's levodopa medication or associated with levodopa induced dyskinesias. Accordingly, we examined the performance of de novo Parkinson patients in a precision lifting task. All patients (n = 6) were newly diagnosed and showed rigidity, bradykinesia, or both, but were unaffected by tremor or dyskinesia. None of the patients had received antiparkinson medication. Grip force was abnormally high in both the lifting and hold phases. This exaggeration was equal in magnitude to that observed previously in medicated patients. Thus we conclude that the abnormalities in grip force observed here are intrinsic features of PD and not the result of dopamine medication or its side effects. (C) 2003 Movement Disorder Society.